EAF Unit 1 Fully Operational; Transition from Blast Furnace/Basic Oxygen Furnace to Electric Arc Furnace Steelmaking Complete Record Plate Sales of 116,000 NT with Further Upside Expected as Plate-First Strategy Scales Adjusted EBITDA in line with Previously Disclosed Guidance SAULT STE. MARIE, Ontario, May 12, 2026 (GLOBE NEWSWIRE) — Algoma Steel Group Inc. (NASDAQ: ASTL; TSX: ASTL) (“Algoma” or “the Company”), a leading Canadian producer of steel plate and hot rolled sheet products, today announced results for the three month period ended March 31, 2026. Unless otherwise specified, all amounts are in Canadian dollars. Business Highlights and First Quarter 2026 to First Quarter 2025 Comparisons Comparisons between Q1 2026 and Q1 2025 were significantly impacted by the transition from legacy blast furnace operations to the Company’s...

TORONTO, May 12, 2026 (GLOBE NEWSWIRE) — “The first quarter of 2026 was an important period for Dundee as it marked a meaningful step in the execution of our strategy,” said Jonathan Goodman, President and Chief Executive Officer of Dundee Corporation. “During the quarter, we closed an $85 million strategic partnership with Westhaven Gold Corp. to advance the Shovelnose Gold Project and the Spences Bridge Gold Belt. This transaction builds on Dundee’s long history as an active and engaged mining investor and represents a meaningful step toward deeper technical involvement, more direct project ownership, and potential future operatorship. In addition, we further strengthened our liquidity position through the sale of our net smelter royalty on the Borborema Gold Project.” “Our recently announced earn-in and joint-venture agreement...

ORLANDO, Fla., May 12, 2026 (GLOBE NEWSWIRE) — Gencor Industries, Inc. (the “Company” or “Gencor”) (NYSE American: GENC) hereby withdraws and retracts its press release dated May 8, 2026, titled “Gencor Industries, Inc. Releases Second Quarter Fiscal 2026 Results” (the “Prior Release”). The Prior Release was issued before the Company had completed its review of the Company’s financial statements for the quarter ended March 31, 2026 and should be disregarded in its entirety. Investors and other recipients should not rely on any information contained in the Prior Release, including the preliminary results of operations for the quarter ended March 31, 2026 reported therein. The Company cautions that no conclusions should be drawn from the Prior Release regarding the Company’s actual financial condition, results of operations, or business...

Robust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI Completion of a $63.2 million public offering to enable clinical trials of EP-104GI in additional indications Well-capitalized into H2 2028, beyond key catalysts with over $140 million cash VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the first quarter of 2026. “The clinical data reported this quarter further reinforces the potential for EP-104GI to become an important new...

CALGARY, Alberta, May 12, 2026 (GLOBE NEWSWIRE) — Total Energy Services Inc. (“Total Energy” or the “Company”) (TSX:TOT) announces its consolidated financial results for the three months ended March 31, 2026. Financial Highlights ($000’s except per share data, unaudited)    Three months endedMarch 31      2026     2025   ChangeRevenue   $ 314,896   $ 251,909   25 %Operating income     27,129     26,063   4 %EBITDA(1)     55,158     50,488   9 %Cashflow     54,290     44,934   21 %Net income     24,222     18,952   28 %Attributable to shareholders     24,137     18,966   27 %                 Per Share Data (Diluted)                EBITDA(1)   $ 1.49   $ 1.31   14 %Cashflow   $ 1.46   $ 1.16   26 %                 Attributable to shareholders:                Net income   $ 0.65   $ 0.49   33 %                 Common...

Q1 2026 revenues were $9.6 million, up 3.1% from $9.3 million in Q1 2025. This represents the highest Q1 quarterly revenues in Company history. Q1 2026 gross margin was 77.3%, versus 79.0% in Q1 2025. GAAP Operating Loss was $1.1 million for Q1 2026, a swing of $1.7 million from operating income of $0.6 million in Q1 2025. Company provides guidance for revenue growth of 10-15% for Q2 2026 as compared to Q2 2025EDEN PRAIRIE, Minn., May 12, 2026 (GLOBE NEWSWIRE) — Sanuwave Health, Inc. (the “Company” or “Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to provide its financial results for the three months ended March 31, 2026. Q1 2026 ended March 31, 2026Revenue for the three months ended March 31, 2026, totaled $9.6 million, an increase of 3.1%,...

VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) — Finning International Inc. (TSX: FTT) (“Finning”, the “Company”, “we”, “our” or “us”) reported first quarter 2026 results today. All monetary amounts are in Canadian dollars unless otherwise stated and all financial information in this earnings release represents the results from continuing operations, unless otherwise noted. (1) HIGHLIGHTSAll comparisons are to Q1 2025 results unless indicated otherwise.Revenue of $2.5 billion was up 2%, led by product support growth in Canada. Product support revenue increased 6% with growth across all market sectors. Q1 2026 was the 8th quarter in a row of year-over-year product support growth. SG&A (2) margin (3) was 16.0% and included $15 million of LTIP (2) expense due to strong first quarter share price performance. EBIT...

Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programs Announced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-11818 is a potent and selective pan-KRAS inhibitor Clinical readouts expected in the second half of 2026 across all three programs Cash runway expected to fund operations into 2028SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) — BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the first quarter ended March 31, 2026, and provided a business update, including highlights of pipeline progress. BBOT’s portfolio of late-stage RAS-pathway inhibitors is designed to enable direct dual inhibition...

TORONTO, May 12, 2026 (GLOBE NEWSWIRE) — Constellation Software Inc. (TSX:CSU) (“Constellation” or the “Company”) today announced its financial results for the first quarter ended March 31, 2026 and declared a $1.00 per share dividend payable on July 10, 2026 to all common shareholders of record at close of business on June 19, 2026. This dividend has been designated as an eligible dividend for the purposes of the Income Tax Act (Canada). Please note that all dollar amounts referred to in this press release are in U.S. Dollars unless otherwise stated. The following press release should be read in conjunction with the Company’s Unaudited Condensed Consolidated Interim Financial Statements for the three months ended March 31, 2026 and the accompanying notes, our Management Discussion and Analysis for the three months ended March...

HOUSTON, May 12, 2026 (GLOBE NEWSWIRE) — Evolution Petroleum Corporation (NYSE American: EPM) (“Evolution” or the “Company”) today announced its financial and operating results for its fiscal third quarter ended March 31, 2026. Evolution also declared its 16th consecutive $0.12 cash dividend per common share, payable on June 30, 2026, marking its 51st consecutive quarterly cash dividend payment. Financial & Operational Highlights($ in thousands) Q3 2026 Q3 2025 Q2 2026 % Changevs Q3/Q3 % Changevs Q3/Q2 2026 YTD 2025 YTD % Changevs YTD’25Average BOEPD   6,700     6,667     7,380 —   (9)%     7,135     7,033   1%Revenues $ 20,168   $ 22,561   $ 20,679 (11)%   (2)%   $ 62,135   $ 64,732   (4)%Net Income (Loss)(1) $ (8,932)   $ (2,179)   $ 1,065 310%   NM   $ (7,043)   $ (1,939)   263%Adjusted...